Fred Chu, MD
Ophthalmology · Blue Ash, OHNPI 1932420478
Payments from drug & device makers
Across 96 payments — averaging $53.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$3K
- Alcon$425
- AbbVie$370
- Aerie Pharmaceuticals, Inc.$228
- Bausch & Lomb Americas Inc.$163
- Glaukos Corporation$159
- plus $840 from 17 others
What the payments were for
- Consulting fees$3,00058%
- Food & beverage$2,18342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Haag-streit USA, Inc. | 1 | $3,000 |
| Alcon | 22 | $425 |
| AbbVie(2 entities) | 15 | $370 |
| Aerie Pharmaceuticals, Inc. | 12 | $228 |
| Bausch & Lomb Americas Inc. | 8 | $163 |
| Glaukos Corporation | 1 | $159 |
| Ivantis, Inc | 3 | $151 |
| Alimera Sciences, Inc. | 4 | $87 |
| Lombart Brothers, Inc. | 3 | $86 |
| Apellis Pharmaceuticals, Inc. | 3 | $71 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $63 |
| Genentech USA, Inc. | 2 | $49 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| NEW World Medical,inc. | 5 | $46 |
| Thea Pharma Inc. | 2 | $41 |
| Amgen(2 entities) | 2 | $39 |
| Novartis | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $26 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$120
How this compares
$5,183 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 301 | $117,426 |
| RocklatanNetarsudil Mesylat/Latanoprost | 195 | $82,212 |
| VyzultaLatanoprostene Bunod | 102 | $37,095 |
| Alphagan PBrimonidine Tartrate | 92 | $36,206 |
| Brimonidine Tartrate | 880 | $18,613 |
| LumiganBimatoprost | 33 | $18,023 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $16,784 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 972 | $14,643 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 106 | $13,372 |
| Methazolamide | 43 | $10,427 |
| Brinzolamide | 81 | $9,353 |
| Latanoprost | 1,173 | $9,075 |
| Prednisolone Acetate | 211 | $8,988 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $8,445 |
| TafluprostTafluprost/Pf | 49 | $8,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $228 | $199,638496 claims |
| AbbVieAlphagan P, Lumigan, Combigan | $370 | $71,012169 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $163 | $37,095102 claims |
| AlconSimbrinza | $425 | $8,44536 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $63 | $3,23618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Blue Ash
- Lucas LindsellBlue Ash$1.3M
- James OsherBlue Ash$793K
- Arjun SoodBlue Ash$99K
- Alison EarlyBlue Ash$69K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.